DE1271116B - Process for the preparation of 4-hydroxypyrimidines - Google Patents
Process for the preparation of 4-hydroxypyrimidinesInfo
- Publication number
- DE1271116B DE1271116B DEP1271A DE1271116A DE1271116B DE 1271116 B DE1271116 B DE 1271116B DE P1271 A DEP1271 A DE P1271A DE 1271116 A DE1271116 A DE 1271116A DE 1271116 B DE1271116 B DE 1271116B
- Authority
- DE
- Germany
- Prior art keywords
- calculated
- found
- carbon atoms
- general formula
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
DEUTSCHESGERMAN
PATENTAMTPATENT OFFICE
Int. Cl.:Int. Cl .:
Deutsche KL:German KL:
Nummer:
Aktenzeichen:
Anmeldetag:
Auslegetag:Number:
File number:
Registration date:
Display day:
C07dC07d
A61kA61k
12 ρ-7/01
30 h-2/3612 ρ -7/01
30 h-2/36
1271116
P 12 71 116.9-44
4. Mai 1965
27.Juni 19681271116
P 12 71 116.9-44
May 4, 1965
June 27, 1968
Gegenstand der Erfindung ist ein Verfahren zur Herstellung von 4-Hydroxypyrimidinen; das Verfahren besteht darin, daß man Essigsäureester der allgemeinen FormelThe invention relates to a process for the preparation of 4-hydroxypyrimidines; the procedure consists in that one acetic acid ester of the general formula
R1 — CH2 — COOR2 IR 1 - CH 2 - COOR 2 I.
in der R1 einen gegebenenfalls durch Halogenatome oder Alkylgruppen mit 1 bis 6 Kohlenstoffatomen
oder durch Alkoxy- oder Alkylmercaptogruppen mit 1 bis 4 Kohlenstoffatomen oder durch Hydroxy-
oder Aminogruppen oder durch Alkylamino- oder Dialkylaminogruppen mit 1 bis 4 Kohlenstoffatomen,
wobei zwei dieser Alkylreste zusammen mit dem Stickstoffatom einen heterocyclischen Ring bilden
können, substituierten Phenyl- oder Naphthylrest darstellt, oder einen gegebenenfalls durch Alkylgruppen
mit 1 bis 6 Kohlenstoffatomen substituierten, 1 bis 3 gleiche oder verschiedene Heteroatome N, S
oder O enthaltenden 5- oder 6gliedrigen Ring, an den auch ein Benzolring anelliert sein kann, bedeutet,
und in der R2 für einen Alkylrest mit 1 bis 6 Kohlenstoffatomen steht, mit Nitrilen der allgemeinen Formel
Verf ahren zur Herstellung von
4-Hydroxypyrimidinenin which R 1 is optionally by halogen atoms or alkyl groups with 1 to 6 carbon atoms or by alkoxy or alkyl mercapto groups with 1 to 4 carbon atoms or by hydroxy or amino groups or by alkylamino or dialkylamino groups with 1 to 4 carbon atoms, two of these alkyl radicals together with the nitrogen atom can form a heterocyclic ring, substituted phenyl or naphthyl radical, or a 5- or 6-membered ring optionally substituted by alkyl groups with 1 to 6 carbon atoms, containing 1 to 3 identical or different heteroatoms N, S or O, on which also a Benzene ring can be fused, and in which R 2 is an alkyl radical having 1 to 6 carbon atoms, with nitriles of the general formula Process for the preparation of
4-hydroxypyrimidines
R3 R 3
CNCN
in der R3 einen 1 bis 3 gleiche oder verschiedene Heteroatome N, S oder O enthaltenden 5- oder 6gliedrigen Ring, an den auch ein Benzolring anelliert sein kann, bedeutet, in Gegenwart einer der Menge des Essigsäureesters mindestens äquimolaren Menge eines Alkalialkoholats eines niederen Alkohols, eines Alkaliamids oder hochsiedenden tertiären Amins, gegebenenfalls in Gegenwart eines inerten organischen Lösungsmittels bei Temperaturen zwischen 60 und 1600C zu 4-Hydroxypyrimidinderivaten der allgemeinen Formelin which R 3 denotes a 5- or 6-membered ring containing 1 to 3 identical or different heteroatoms N, S or O, to which a benzene ring can also be fused, in the presence of an amount of an alkali metal alcoholate of a lower alcohol which is at least equimolar to the amount of the acetic acid ester , an alkali amide or high-boiling tertiary amine, optionally in the presence of an inert organic solvent at temperatures between 60 and 160 ° C. to give 4-hydroxypyrimidine derivatives of the general formula
OHOH
in der R1 und R3 die oben angegebenen Bedeutungen haben, umsetzt.in which R 1 and R 3 have the meanings given above.
Für die Durchführung des erfindungsgemäßen Verfahrens geeignete Essigsäureester der allgemeinen Formel I sind z. B. Phenylessigsäuremethylester, -äthylester, -isopropylester und -butylester, «- und /y-Naphthylessigsäureäthylester, o-, m- und p-Methylphenylessigsäureäthylester, o-, m- und p-Methoxyphenylessigsäureäthylester, o-, m- und p-Methylmercaptophenylessigsäurcäthylester, o-, m- und p-Hydroxy-For carrying out the process according to the invention, suitable acetic acid esters of the general Formula I are e.g. B. Phenylacetic acid methyl ester, ethyl ester, isopropyl ester and butyl ester, «- and / y-naphthylacetic acid ethyl ester, o-, m- and p-methylphenylacetic acid ethyl ester, o-, m- and p-methoxyphenylacetic acid ethyl ester, o-, m- and p-methyl mercaptophenylacetic acid ethyl ester, o-, m- and p-hydroxy
Anmelder:Applicant:
Farbenfabriken Bayer Aktiengesellschaft,Paint factories Bayer Aktiengesellschaft,
5090 Leverkusen5090 Leverkusen
Als Erfinder benannt:Named as inventor:
Dr. Hans-Joachim Kabbe, 5090 Leverkusen;Dr. Hans-Joachim Kabbe, 5090 Leverkusen;
Dr. Karl Eiter, 5000 Köln-StammheimDr. Karl Eiter, 5000 Cologne-Stammheim
phenylessigsäureäthylester, o- und p-Chlorphenylessigsäureäthylester, 3 - Chlor - 4 - methoxyphenylessigsäureäthylester, 3,4 - Dichlorphenylessigsäureäthylester, 3,5 - Dichlor - 4- methoxyphenylessigsäureäthylester, 2-Methoxy-4-methyl-5-chlorphenylessigsäureäthylester, p-Aminophenylessigsäureäthylester, p-Methylaminophenylessigsäureäthylester, ρ - Dimethylaminophenylessigsäureäthylester, p-Pyrrolidinophenylessigsäureäthylester, α - Furylessigsäureäthylester, α-, β- und y-Pyridylessigsäureäthylester, 5-Thiazolylessigsäureäthylester, 5 - Oxazolylessigsäureäthylester, 1 - vic - Triazolylessigsäureäthylester und 2 - Benzimidazolylessigsäureäthylester. phenylacetic acid ethyl ester, o- and p-chlorophenylacetic acid ethyl ester, 3 - chloro - 4 - methoxyphenylacetic acid ethyl ester, 3,4 - dichlorophenylacetic acid ethyl ester, 3,5 - dichloro - 4-methoxyphenylacetic acid ethyl ester, 2-methoxy-4-methyl-5-chlorophenylacetic acid ethyl ester, p-ethyl aminophenylacetate, p- -Methylaminophenylacetic acid ethyl ester, ρ - dimethylaminophenylacetic acid ethyl ester, p-pyrrolidinophenylacetic acid ethyl ester, α - furyl acetic acid ethyl ester, α-, β- and γ-pyridyl acetic acid ethyl ester, 5-thiazolylacetic acid ethyl ester, 5-oxazolylacetic acid ethyl ester, 2 acetylacetate, 5-oxazolylacetyl acetic acid ethyl ester, benzoliacetyl acetate, benzyl acetate, 5-oxazolylacetyl acetate, benzyl acetate, ethyl acetate.
Geeignete Nitrile der allgemeinen Formel II sind beispielsweise 2-Cyanopyrrol, 2-Cyanofuran, 2-Cyanothiophen, α-, β- und y-Cyanopyridin, 4- und 5-Cyanothiazol, 4- und 5-Cyanooxazol, 4-Cyanopyrimidin und 3-Cyanochinolin.Suitable nitriles of the general formula II are, for example, 2-cyanopyrrole, 2-cyanofuran, 2-cyanothiophene, α-, β- and γ-cyanopyridine, 4- and 5-cyanothiazole, 4- and 5-cyanooxazole, 4-cyanopyrimidine and 3- Cyanoquinoline.
Das Molverhältnis zwischen Essigsäureestern und Nitrilen beträgt im allgemeinen 1:1,5 bis 1:3, zweckmäßig 1:2.The molar ratio between acetic acid esters and nitriles is generally 1: 1.5 to 1: 3, expedient 1: 2.
Als Alkalialkoholate eignen sich z. B. Kalium- und Natriummethylat, -äthylat, -tert.butylat, als Alkaliamide ζ. B. Kalium- und Natriumamid, als hochsiedende tertiäre Amine ζ. B. Dimethylanilin, Collidin und Chinolin.Suitable alkali metal alcoholates are, for. B. potassium and sodium methylate, ethylate, tert-butylate, as alkali amides ζ. B. potassium and sodium amides, as high-boiling tertiary amines ζ. B. dimethylaniline, collidine and quinoline.
Die Umsetzung, deren Dauer 15 Minuten bis 10 Stunden beträgt, wird vorzugsweise zwischen 100 und 130' C durchgeführt. Falls Lösungsmittel verwendet werden, müssen sie gegenüber den zur Anwendung gelangenden Essigsäureestern und Nitrilen sowie gegenüber den oben angegebenen basischen Verbindungen inert sein und, falls die Umsetzung unterImplementation, the duration of which is 15 minutes up 10 hours is preferably carried out between 100 and 130 ° C. If solvent is used they must be compared to the acetic acid esters and nitriles used as well be inert towards the basic compounds given above and, if the reaction is below
809 567/566809 567/566
normalem Druck vorgenommen wird, mindestens einen der Umsetzungstemperatur entsprechenden Siedepunkt besitzen. Als Beispiele seien genannt Kohlenwasserstoffe, wie Benzol, Toluol und Xylol, Äther, wie Dibutyläther und Glykoldiäthyläther, Alkohole, wie Butanol und Pentanol, und chlorierte Kohlenwasserstoffe, wie Tetrachlorkohlenstoff, Di-1 chloräthan und Chlorbenzol.normal pressure is carried out, at least one corresponding to the reaction temperature Have boiling point. Examples are hydrocarbons such as benzene, toluene and xylene, Ethers such as dibutyl ether and glycol diethyl ether, alcohols such as butanol and pentanol, and chlorinated ones Hydrocarbons such as carbon tetrachloride, di-1 chloroethane and chlorobenzene.
Die nach dem erfindungsgemäßen Verfahren überraschenderweise erhaltenen neuen 4-Hydroxypyrimidine der allgemeinen Formel III besitzen eine bemerkenswerte Wirkung gegenüber Bakterien, wie Streptokokken, Staphylokokken, Colibakterien, Proteusbakterien und Tuberkelbakterien, sowie gegen Pilze, wie Trichophyton mentagrophytes und Candida albicans.Surprisingly, by the process according to the invention obtained new 4-hydroxypyrimidines of the general formula III have a remarkable Effect on bacteria such as streptococci, staphylococci, coli bacteria, proteus bacteria and tubercle bacteria, as well as against fungi such as Trichophyton mentagrophytes and Candida albicans.
Die in den folgenden Beispielen angegebenen Teile sind Gewichtsteile.The parts given in the following examples are parts by weight.
33 Teile Phenylessigsäureäthylester (0,2 Mol) und 42 Teile a-Cyanopyridin (0,4 Mol) wurden bei Raumtemperatur mit 12 Teilen Natriummethylat (0,22 Mol) verrührt und dann erwärmt. Bei 60° C trat eine stark exotherme Reaktion ein, und die Temperatur stieg dann bis auf 115° C. Die Reaktionsmischung wurde anschließend noch 20 Minuten auf 1100C gehalten, dann abgekühlt und in 250 Teilen Wasser gelöst. Aus der erhaltenen Lösung wurde durch Zugabe von 100 Teilen gesättigter wäßriger Ammoniumchloridlösung das gebildete 2,6-Di-a-pyridyl-4-hydroxy-5-phenylpyrimidin ausgefällt. Die Ausbeute betrug 40 Teile (= 62%), Schmelzpunkt 227 bis 228,5° C (nach dem Umkristallisieren aus Eisessig—Wasser).33 parts of ethyl phenylacetate (0.2 mol) and 42 parts of α-cyanopyridine (0.4 mol) were stirred with 12 parts of sodium methylate (0.22 mol) at room temperature and then heated. At 60 ° C, a strongly exothermic reaction occurred, and the temperature then rose to 115 ° C. The reaction mixture was then another 20 minutes to 110 0 C held, then cooled and dissolved in 250 parts of water. The 2,6-di-a-pyridyl-4-hydroxy-5-phenylpyrimidine formed was precipitated from the solution obtained by adding 100 parts of saturated aqueous ammonium chloride solution. The yield was 40 parts (= 62%), melting point 227 to 228.5 ° C. (after recrystallization from glacial acetic acid-water).
Analyse: C20H14N4O (326,35).Analysis: C 20 H 14 N 4 O (326.35).
Berechnet ... C 73,61, H 4,33, N 17,17%;
gefunden .... C 73,73, H 4,66, N 16,95%.Calculated ... C 73.61, H 4.33, N 17.17%;
found .... C 73.73, H 4.66, N 16.95%.
Eine Mischung aus 33 Teilen Phenylessigsäureäthylester 0,2 Mol), 42 Teilen γ - Cyanopyridin (0,4 Mol) und 80 Teilen Butanol wurde mit 12 Teilen Natriummethylat (0,22 Mol) versetzt und IV2 Stunden bei HO0C gerührt. Dann wurde die Reaktionsmischung in 250 Teilen Wasser gelöst. Durch Zugabe von 100 Teilen gesättigter wäßriger Ammoniumchloridlösung wurde das gebildete 2,6-Di-y-pyridyl-4-hydroxy-5-phenylpyrimidin ausgefällt. Die Ausbeute betrug 61 Teile (= 800/o), Schmelzpunkt 300 bis 3050C (nach dem Umkristallisieren aus Eisessig— Wasser).A mixture of 33 parts of phenylacetic acid ethyl ester (0.2 mol), 42 parts of γ- cyanopyridine (0.4 mol) and 80 parts of butanol was mixed with 12 parts of sodium methylate (0.22 mol) and stirred at HO 0 C for IV2 hours. Then the reaction mixture was dissolved in 250 parts of water. The 2,6-di-y-pyridyl-4-hydroxy-5-phenylpyrimidine formed was precipitated by adding 100 parts of saturated aqueous ammonium chloride solution. The yield was 61 parts (= 80 0 / o), m.p. 300-305 0 C (after recrystallization from glacial acetic acid water).
Analyse: C20H14N4O · CH3COOH (386,39).
Berechnet ... N 14,50%;
gefunden .... N 14,67%.Analysis: C 20 H 14 N 4 O • CH 3 COOH (386.39).
Calculated ... N 14.50%;
found .... N 14.67%.
Verwendete man an Stelle von Natriummethylat die äquivalente Menge an Kalium-tert.-butylat, so erhielt man das 2,6-Di-y-pyridyl-4-hydroxy-5-phenylpyrimidin in 78%iger Ausbeute.If the equivalent amount of potassium tert-butoxide was used instead of sodium methylate, see above the 2,6-di-y-pyridyl-4-hydroxy-5-phenylpyrimidine was obtained in 78% yield.
In analoger Weise wurden die aus der folgenden Tabelle ersichtlichen Essigsäureäthylester der allgemeinen Formel I in Gegenwart von Natriummethylat mit Nitrilen der allgemeinen Formel II zu den entsprechenden 4-Hydroxypyrimidinen der allgemeinen Formel III umgesetzt.In an analogous manner, the ethyl acetate shown in the following table were the general Formula I in the presence of sodium methylate with nitriles of the general formula II converted to the corresponding 4-hydroxypyrimidines of the general formula III.
Die Umsetzung des in der Tabelle unter n) angeführten 3,4-DichlorphenyIessigsäureäthylesters mit 2-Cyanofuran wurde ohne Mitverwendung eines Lösungsmittels vorgenommen; die Umsetzung des unter a) angeführten Phenylessigsäureäthylesters mit ^-Cyanopyridin erfolgte unter Mitverwendung von Pentanol als Lösungsmittel, und die übrigen Umsetzungen wurden unter Mitverwendung von Butanol als Lösungsmittel durchgeführt.The implementation of the 3,4-dichlorophenyl acetic acid ethyl ester listed in the table under n) with 2-cyanofuran was carried out without the use of a solvent; the implementation of the under a) listed phenylacetic acid ethyl ester with ^ -Cyanopyridin took place with the use of Pentanol as the solvent, and the remaining reactions were carried out with the use of butanol carried out as a solvent.
Reaktions
temperaturResponse time /
Reaction
temperature
beutethe end
prey
in 0CMelting point
in 0 C
1100C3 hours
110 0 C
berechnet: N 17,17;
gefunden: N 16,98.C 20 H 14 N 4 O
calculated: N 17.17;
found: N 16.98.
IOH
I.
\ /\ /
1100C2 hours
110 0 C
(Zersetzung)320
(Decomposition)
berechnet: N 15,63;
gefunden: N 15,28.C 20 H 14 N 4 O 3
calculated: N 15.63;
found: N 15.28.
110° C4 hours
110 ° C
berechnet: N 15,55, Cl 9,83;
gefunden: N 15,55, Cl 9,90.C 20 H 13 ClN 4 O
Calculated: N 15.55, Cl 9.83;
found: N 15.55, Cl 9.90.
110° C3 hours
110 ° C
berechnet: Cl 9,83;
gefunden: Cl 9,85.C 20 H 13 ClN 4 O
calculated: Cl 9.83;
found: Cl 9.85.
Fortsetzungcontinuation
R1 R 1
R3 R 3
Reaktionsdauer/ Reaktionstemperatur Reaction time / reaction temperature
Ausbeute yield
Schmelzpunkt
in °CMelting point
in ° C
Summenformel von HIMolecular formula of HI
ClCl
CH3OCH 3 O
3 Stunden 1100C3 hours 110 ° C
3 Stunden 1100C3 hours 110 ° C
4 Stunden 1100C4 hours 110 ° C
5 Stunden 1050C5 hours 105 ° C
I1I2 Stunden HO0C I 1 I 2 hours HO 0 C
3 Stunden 1150C3 hours 115 ° C
3 Stunden 105° C3 hours 105 ° C
2 Stunden 1100C2 hours 110 ° C
1 Stunde 1100C1 hour 110 ° C
4 Stunden 1050C4 hours 105 ° C
6 Stunden 1080C6 hours 108 0 C
IV2 Stunden 105°CIV2 hours 105 ° C
bis 295to 295
bis 222to 222
bis 285to 285
>330> 330
bis 252to 252
212 bis 213212 to 213
bis 286to 286
bis 303to 303
bis 266to 266
320320
bis 252to 252
bis 221to 221
C20H13ClN4OC 20 H 13 ClN 4 O
berechnet: N 15,53, Cl 9,83; gefunden: N 15,48, Cl 9,85.Calculated: N 15.53, Cl 9.83; found: N 15.48, Cl 9.85.
C20H13ClN4OC 20 H 13 ClN 4 O
berechnet: Cl 9,83; gefunden: Cl 9,95.calculated: Cl 9.83; found: Cl 9.95.
C20H13ClN4OC 20 H 13 ClN 4 O
berechnet: N 15,53; gefunden: N 15,33.calculated: N 15.53; found: N 15.33.
C20H13ClN4OC 20 H 13 ClN 4 O
berechnet: N 15,53, Cl 9,83; gefunden: N 15,15, Cl 9,80.Calculated: N 15.53, Cl 9.83; found: N 15.15, Cl 9.80.
C21H15ClN4O2 C 21 H 15 ClN 4 O 2
berechnet: N 14,34, Cl 9,07; gefunden: N 14,36, Cl 8,75.Calculated: N 14.34, Cl 9.07; found: N 14.36, Cl 8.75.
C20H12Cl2N4OC 20 H 12 Cl 2 N 4 O
berechnet: N 14,18, Cl 17,94; gefunden: N 14,19, Cl 17,55.Calculated: N 14.18, Cl 17.94; found: N 14.19, Cl 17.55.
C20N12Cl2N4OC 20 N 12 Cl 2 N 4 O
berechnet: Cl 17,94; gefunden: Cl 18,15.calculated: Cl 17.94; found: Cl 18.15.
C20H12Cl2N4O · 1,5 CH3COOHC 20 H 12 Cl 2 N 4 O.1.5 CH 3 COOH
berechnet: N 11,54; gefunden: N 11,40.calculated: N 11.54; found: N 11.40.
C18H10Cl2N2O3 C 18 H 10 Cl 2 N 2 O 3
berechnet: N 7,51, O 12,88; gefunden: N 7,53, 0 13,13.Calculated: N 7.51, O 12.88; found: N 7.53, 0 13.13.
C20H12ClN4OC 20 H 12 ClN 4 O
berechnet:calculated:
C 60,77, H 3,06, N 14,17; gefunden:C 60.77, H 3.06, N 14.17; found:
C 60,44, H 3,25, N 14,37.C 60.44, H 3.25, N 14.37.
C24H16N4OC 24 H 16 N 4 O
berechnet: N 14,88; gefunden: N 14,70.calculated: N 14.88; found: N 14.70.
C19H13N5OC 19 H 13 N 5 O
berechnet:calculated:
C 69,71, H 4,01, N 21,40; gefunden:C 69.71, H 4.01, N 21.40; found:
C 69,37, H 4,27, N 20,97.C 69.37, H 4.27, N 20.97.
Fortsetzungcontinuation
R1 R 1
R3 R 3
Reaktionsdauer/ Reaktionstemperatur Reaction time / reaction temperature
Ausbeute Schmelzpunkt
in 0CYield melting point
in 0 C
Summenformel von IIIMolecular formula of III
Q-Q-
4 Stunden 115°C4 hours 115 ° C
2 Stunden 1080C2 hours 108 0 C
IV2 Stunden 1150CIV2 hours 115 0 C
Claims (1)
(Zersetzung)230
(Decomposition)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP1271A DE1271116B (en) | 1965-05-04 | 1965-05-04 | Process for the preparation of 4-hydroxypyrimidines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP1271A DE1271116B (en) | 1965-05-04 | 1965-05-04 | Process for the preparation of 4-hydroxypyrimidines |
DEF0045958 | 1965-05-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE1271116B true DE1271116B (en) | 1968-06-27 |
Family
ID=25751381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DEP1271A Pending DE1271116B (en) | 1965-05-04 | 1965-05-04 | Process for the preparation of 4-hydroxypyrimidines |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE1271116B (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0557860A1 (en) * | 1992-02-28 | 1993-09-01 | Bayer Ag | Substituted pyridiylpyrimidines and their use as parasiticide |
WO1998024780A2 (en) * | 1996-12-05 | 1998-06-11 | Amgen Inc. | Substituted pyrimidinone and pyridinone compounds and their use |
WO1998024782A2 (en) * | 1996-12-05 | 1998-06-11 | Amgen Inc. | Substituted pyrimidine compounds and their use |
US6096753A (en) * | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
US6410729B1 (en) | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
EP1314732A2 (en) * | 1996-12-05 | 2003-05-28 | Amgen Inc. | Substituted pyrimidine compounds and their use |
WO2005099711A1 (en) * | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
US11993580B1 (en) | 2023-12-01 | 2024-05-28 | Neumora Therapeutics, Inc. | Methods of treating neurological disorders |
-
1965
- 1965-05-04 DE DEP1271A patent/DE1271116B/en active Pending
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0557860A1 (en) * | 1992-02-28 | 1993-09-01 | Bayer Ag | Substituted pyridiylpyrimidines and their use as parasiticide |
US5385905A (en) * | 1992-02-28 | 1995-01-31 | Bayer Aktiengesellschaft | Substituted pyridylpyrimidines |
WO1998024780A2 (en) * | 1996-12-05 | 1998-06-11 | Amgen Inc. | Substituted pyrimidinone and pyridinone compounds and their use |
WO1998024782A2 (en) * | 1996-12-05 | 1998-06-11 | Amgen Inc. | Substituted pyrimidine compounds and their use |
WO1998024780A3 (en) * | 1996-12-05 | 1998-07-30 | Amgen Inc | Substituted pyrimidinone and pyridinone compounds and their use |
WO1998024782A3 (en) * | 1996-12-05 | 1998-08-27 | Amgen Inc | Substituted pyrimidine compounds and their use |
US6096753A (en) * | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
US6410729B1 (en) | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
US6420385B1 (en) | 1996-12-05 | 2002-07-16 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
EP1314732A2 (en) * | 1996-12-05 | 2003-05-28 | Amgen Inc. | Substituted pyrimidine compounds and their use |
EP1314731A2 (en) * | 1996-12-05 | 2003-05-28 | Amgen Inc. | Substituted pyrimidine compounds and their use |
US6610698B2 (en) | 1996-12-05 | 2003-08-26 | Amgen, Inc. | Substituted pyrimidine compounds and methods of use |
US6649604B2 (en) | 1996-12-05 | 2003-11-18 | Amgen Inc. | Substituted pyridone compounds and methods of use |
EP1314732A3 (en) * | 1996-12-05 | 2004-01-02 | Amgen Inc. | Substituted pyrimidine compounds and their use |
EP1314731A3 (en) * | 1996-12-05 | 2004-01-02 | Amgen Inc. | Substituted pyrimidine compounds and their use |
WO2005099711A1 (en) * | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
US7560464B2 (en) | 2004-04-13 | 2009-07-14 | Icagen, Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
US11993580B1 (en) | 2023-12-01 | 2024-05-28 | Neumora Therapeutics, Inc. | Methods of treating neurological disorders |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE1670529C3 (en) | Substituted s-triazines | |
DE1470439B1 (en) | Quinoline derivatives and processes for their preparation | |
DE2237632C3 (en) | H4-Hydro3qr-6-methyl-2-pvrimidinyD-3-methyl-pyrazolin-5-one, a process for its preparation and its use for the preparation of 1- (4-methoxy-6methyl-2-pyrimidinyl) -3-methyl -5-methoxypyrazole | |
DE1271116B (en) | Process for the preparation of 4-hydroxypyrimidines | |
DE1169939B (en) | Process for the preparation of dihalo-aminobenzylamines or their acid addition salts with physiologically acceptable acids | |
DE2141616C3 (en) | Oxazole- and Oxazine square bracket on 3.2-c square bracket for quinazolinone, process for their preparation and medicinal products containing these compounds | |
DE2841644C2 (en) | ||
DE1795344A1 (en) | 3-amino-isothiazoles | |
CH638203A5 (en) | Process for preparing substituted aminoquinazoline derivatives | |
DE2804263C3 (en) | Process for the preparation of indoline derivatives | |
DE1233405B (en) | Process for the preparation of 7- (oxoalkyl) -1, 3-dimethylxanthines | |
DE2162917C3 (en) | ||
DE2407904A1 (en) | D-2-SUBST.-6-ALKYL-8-SUBST.-ERGOLINE AND THE PROCESS FOR THEIR PRODUCTION | |
DE1770922A1 (en) | New triazine derivatives and processes for their preparation | |
DE1000387C2 (en) | Process for the preparation of new 1, 10-diazaanthracenes substituted in the 9-position | |
DE1695757C3 (en) | Pyridine methanol carbamates and processes for their preparation | |
DE1135478B (en) | Process for the preparation of 3, 5-dioxo-1, 2, 4-triazolidines | |
DE1695757B2 (en) | PYRIDINE METHANOL CARBAMATES AND PROCESS FOR THE PREPARATION | |
DE1083803B (en) | Process for the preparation of derivatives of anthranil-N-carboxylic acid | |
AT394193B (en) | Process for the preparation of novel 5-fluoronicotinic acids or derivatives and salts thereof | |
AT266838B (en) | Process for the preparation of benzodiazepine derivatives | |
DE1720012C3 (en) | Process for the preparation of 2,4-diamino-5- (3,4,5-trimethoxybenzyl) pyrimidine | |
DE1670730A1 (en) | Process for the preparation of quinoxaline di-N-oxides | |
DE3229215A1 (en) | 1- (HALOGENALKYL) -1,2,3,4-TETRAHYDRO-SS-CARBOLINE, THEIR PRODUCTION AND USE | |
DE1518633A1 (en) | Process for the preparation of pharmaceutically active derivatives of 2-aminoindane |